Organon (OGN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
The meeting was opened virtually to increase inclusivity and participation, with shareholders able to vote and ask questions online.
The agenda included introductions, formal business, and voting on key proposals.
Rules of conduct and technical support information were provided to ensure an orderly meeting.
Board and executive committee updates
All board members and executive officers were present, including committee chairs for ESG, Talent, Portfolio Development, and Audit.
The independent registered public accounting firm and inspector of election were also in attendance.
Shareholder proposals
Proposals included election of directors, advisory vote on executive compensation, amendment of the 2021 Incentive Stock Plan, and ratification of the accounting firm.
The board unanimously recommended voting in favor of all proposals.
Latest events from Organon
- Shareholders will soon vote on the Sun Pharma acquisition amid strong performance and cultural focus.OGN
Proxy filing11 Jun 2026 - Shareholders to vote on $14.00 per share all-cash merger with Sun Pharma USA, closing expected in 2027.OGN
Proxy filing1 Jun 2026 - Net income rose 68% to $146 million on $1.46 billion revenue, with a pending merger and remediation.OGN
Q1 20264 May 2026 - Organon and Sun Pharma announce a merger with strong employee protections and a pending shareholder vote.OGN
Proxy filing30 Apr 2026 - Pending merger with Sun Pharma and Q1 2026 revenue decline highlight key developments.OGN
Proxy filing30 Apr 2026 - Definitive agreement for acquisition by Sun Pharma; shareholder vote and leadership continuity planned.OGN
Proxy filing27 Apr 2026 - Board approves Sun Pharma acquisition, citing value, mission, and continuity; shareholder vote pending.OGN
Proxy filing27 Apr 2026 - Organon to be acquired by Sun Pharma for $11.75Bn in a cash deal at a 103% premium.OGN
Proxy filing27 Apr 2026 - Sun Pharma to acquire Organon for $14/share in cash, creating a top 25 global pharma company.OGN
Proxy filing27 Apr 2026